Sengkang Health

sengkanghealth.com.sg

Sengkang Health forms a vital part of Singapore’s master plan in providing innovative, quality and accessible healthcare to our vibrant island nation of over five million people. Nestled in the northeast heartland, it will offer cutting-edge general hospital competencies with community-based care. As a member of SingHealth, Singapore’s largest academic healthcare cluster, Sengkang General and Community Hospitals will augment SingHealth’s infrastructure in delivering a full spectrum of care to meet our population’s growing healthcare needs. With a strong community focus, Sengkang Health envisions building an ecosystem of healthy living for the benefit of residents in northeast Singapore.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT

XILIO THERAPEUTICS TO HOST LIVE VIRTUAL PROGRAM SPOTLIGHTING XTX301, A TUMOR-ACTIVATED IL-12

Xilio Therapeutics, Inc. | November 28, 2022

news image

Xilio Therapeutics, Inc. a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, announced that the company will host a live virtual program on Thursday, December 1, 2022, at 12:30 p.m. ET spotlighting Xilio’s clinical-stage molecule XTX301, a tumor-activated, engineered IL-12. The event will feature Diwakar Davar, MBBS, M.Sc., a key opinion leader and assistant professor of medicine and a medical oncologist/hematologist fr...

Read More

GILEAD TO ACQUIRE IMMUNO-ONCOLOGY COMPANY FORTY SEVEN FOR $4.9 BILLION

BioSpace | March 02, 2020

news image

Gilead Sciences is buying Forty Seven for $95.50 per share, or a deal value of $4.9 billion. The deal was unanimously approved by both companies’ boards. Gilead picks up Forty Seven’s lead product candidate, magrolimab, a monoclonal antibody in the clinic for several cancers, including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL). Magrolimab targets CD47. Forty Seven presented positive results from a Phase Ib trial of the drug...

Read More

MEDTECH

PATRITUMAB DERUXTECAN GRANTED U.S. FDA BREAKTHROUGH THERAPY DESIGNATION IN PATIENTS WITH METASTATIC EGFR-MUTATED NON-SMALL CELL LUNG CANCER

Daiichi Sankyo | December 24, 2021

news image

Daiichi Sankyo Company, Limited announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to patritumab deruxtecan, a potential first-in-class HER3 directed antibody drug conjugate, for the treatment of patients with metastatic or locally advanced EGFR-mutated non-small cell lung cancer with disease progression on or after treatment with a third-generation tyrosine kinase inhibitor and platinum-based therapies. Lung cancer is the second most...

Read More

MEDTECH

SEQUENCE BIO ANNOUNCES DISCOVERY COLLABORATION AGREEMENT WITH LEO PHARMA

Sequence Bio | April 08, 2022

news image

Sequence Bio, a Newfoundland and Labrador-based discovery biology company, announced today that it has entered into a collaboration agreement with Danish dermatology specialists LEO Pharma, for use of Sequence Bio's proprietary discovery platform to identify novel dermatologic drug targets. Under the terms of the three year agreement, Sequence Bio will perform multi-omic analyses of samples from powered discovery cohorts across multiple dermatologic indications. LEO Pharma will leverage insi...

Read More
news image

INDUSTRIAL IMPACT

XILIO THERAPEUTICS TO HOST LIVE VIRTUAL PROGRAM SPOTLIGHTING XTX301, A TUMOR-ACTIVATED IL-12

Xilio Therapeutics, Inc. | November 28, 2022

Xilio Therapeutics, Inc. a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, announced that the company will host a live virtual program on Thursday, December 1, 2022, at 12:30 p.m. ET spotlighting Xilio’s clinical-stage molecule XTX301, a tumor-activated, engineered IL-12. The event will feature Diwakar Davar, MBBS, M.Sc., a key opinion leader and assistant professor of medicine and a medical oncologist/hematologist fr...

Read More
news image

GILEAD TO ACQUIRE IMMUNO-ONCOLOGY COMPANY FORTY SEVEN FOR $4.9 BILLION

BioSpace | March 02, 2020

Gilead Sciences is buying Forty Seven for $95.50 per share, or a deal value of $4.9 billion. The deal was unanimously approved by both companies’ boards. Gilead picks up Forty Seven’s lead product candidate, magrolimab, a monoclonal antibody in the clinic for several cancers, including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL). Magrolimab targets CD47. Forty Seven presented positive results from a Phase Ib trial of the drug...

Read More
news image

MEDTECH

PATRITUMAB DERUXTECAN GRANTED U.S. FDA BREAKTHROUGH THERAPY DESIGNATION IN PATIENTS WITH METASTATIC EGFR-MUTATED NON-SMALL CELL LUNG CANCER

Daiichi Sankyo | December 24, 2021

Daiichi Sankyo Company, Limited announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to patritumab deruxtecan, a potential first-in-class HER3 directed antibody drug conjugate, for the treatment of patients with metastatic or locally advanced EGFR-mutated non-small cell lung cancer with disease progression on or after treatment with a third-generation tyrosine kinase inhibitor and platinum-based therapies. Lung cancer is the second most...

Read More
news image

MEDTECH

SEQUENCE BIO ANNOUNCES DISCOVERY COLLABORATION AGREEMENT WITH LEO PHARMA

Sequence Bio | April 08, 2022

Sequence Bio, a Newfoundland and Labrador-based discovery biology company, announced today that it has entered into a collaboration agreement with Danish dermatology specialists LEO Pharma, for use of Sequence Bio's proprietary discovery platform to identify novel dermatologic drug targets. Under the terms of the three year agreement, Sequence Bio will perform multi-omic analyses of samples from powered discovery cohorts across multiple dermatologic indications. LEO Pharma will leverage insi...

Read More